Medgenics Inc Admission of Shares to AIM (6956W)
January 30 2013 - 5:03AM
UK Regulatory
TIDMMEDG TIDMMEDU
RNS Number : 6956W
Medgenics Inc
30 January 2013
Press Release 30 January 2013
Medgenics, Inc.
("Medgenics" or the "Company")
Admission of Shares to AIM
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the
developer of Biopump(TM) , a novel technology for the sustained
production and delivery of therapeutic proteins in patients using
their own tissue, today announces that on November 1, 2012 it
entered into an agreement with Corporate Profile LLC to provide
consultancy services and advice to the Company with regard to
investor relations and media. Part of the consideration for such
services was the issuance of 30,000 restricted common shares which
have been issued and allotted conditional upon admission to trading
on AIM.
On December 1, 2012 the Company also entered into an agreement
with Platinum VIII Investments and Media LLC ("Platinum") to
provide consultancy services and advice to the Company with regard
to investor relations and media. Part of the consideration for such
services was the initial issuance of 25,000 restricted common
shares which have been issued and allotted conditional upon
admission to trading on AIM and an additional issuance of 5,000
restricted common shares to Platinum each month for the next 5
months.
Application has been made to the London Stock Exchange for these
issued restricted common shares to be admitted to trading on AIM
and admission is expected to commence on or around February 4,
2013.
- Ends -
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia, hepatitis and hemophilia, among others. For more
information, visit the Company's website at www.medgenics.com.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend, "
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900
Dr. Andrew L. Pearlman
Andrew.pearlman@medgenics.com
Abchurch Communications Phone: +44 207 398 7719
Adam Michael
Joanne Shears
Jamie Hooper
jamie.hooper@abchurch-group.com
Nomura Code Securities (NOMAD/Broker) Phone: +44 207 776 1219
Jonathan Senior
Giles Balleny
SVS Securities plc (Joint Broker) Phone: +44 207 638 5600
Alex Mattey
Ian Callaway
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAFFEDEFDEFF
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jul 2023 to Jul 2024